Pusic I, Miklos D, Cutler C, et al. Ibrutinib for chronic graft-versus-host disease after failure of frontline corticosteroids: results of a multicenter open-label phase 2-study. EHA 2017, S492.
Epcoritamab en tislelizumab in de sluis geplaatst
nov 2023 | Lymfoom, Maag-darm-leveroncologie